Xconomy

AUGUST 2, 2019

Investors, however, buoyed the company’s share price this week after Acadia (NASDAQ: ACAD ) announced it anticipated that sales of Nuplazid, its sole commercial drug, Read more » Reprints | Share: UNDERWRITERS AND PARTNERS.

Pricing 61

Pricing Sales Company Companies 61

Xconomy

DECEMBER 4, 2017

9 announcement , the price of Dynavax shares slipped about 8 percent, from $20.05 To him, vaccines represent a paradigm in preventive health—even though vaccines take longer to develop and typically don’t bring. In the days following the company’s Nov. a share to $18.45

Carson 75

Carson Develop Development News 75

Xconomy

NOVEMBER 19, 2018

Cibus, which has developed a proprietary gene-editing technology that tweaks crops’ DNA to improve yield, is planning to make its public market debut. The San Diego-based biotech set a preliminary $100 million target for its IPO in documents filed with securities regulators Friday.

San Diego 72

San Diego Research Startup Pricing 72

Xconomy

AUGUST 17, 2018

We also saw a new biotech emerge in the muggy New York heat, a couple deals for new flu vaccines, and interesting developments in the complicated world of drug pricing. Both were landmarks for the companies receiving the nod, Alnylam Pharmaceuticals and Amicus Therapeutics. It’s hot out there. Stay cool with the roundup.

Pricing 52

Pricing Venture Capital Develop Development 52

Xconomy

JULY 31, 2020

This week the neuroscience drug developer reached a deal to merge with publicly traded Arya Sciences Acquisition Corp II. The biotech IPO market is buzzing but Cerevel Therapeutics is showing that there’s more than one path to the public markets.

Pricing 72

Pricing Acquisition Capital Marketing 72

Xconomy

JANUARY 5, 2018

Two other big questions we raised immediately became topics of conversation this week, thanks to Spark Therapeutics, which set the price for its gene therapy—the first ever approved in the U.S.—at We also covered gene therapy development news. —at $850,000. Read more » Reprints | Share:

Pricing 55

Pricing News Develop Development 55

Xconomy

APRIL 13, 2017

Tocagen has been developing a gene therapy treatment for a deadly type of brain cancer. San Diego-based Tocagen (NASDAQ: TOCA ) priced its offering of 8.5 million shares priced between $10 to $12 each. million shares at $10 per share. The company had previously planned to sell 7.25

San Diego 66

San Diego Pricing Demand Marketing 66

Xconomy

JANUARY 31, 2020

million more shares than anticipated and pricing at the high end of its planned range. The stock price closed at $21.80, up 28 percent. The company joins the public markets with four product candidates in its pipeline, all topical non-steroidal treatments being developed for seven dermatological indications.

Westlake Village 114

Westlake Village Pricing Develop Development 114

Xconomy

OCTOBER 26, 2018

Munich, Germany, hosted the annual conference of the European Society for Medical Oncology, where cancer drug developers unveiled the latest clinical data for experimental immunotherapies and drugs that treat the disease based on a tumor’s genetic signature. Read more » Reprints | Share:

Pricing 86

Pricing Conference Research Invest 86

Xconomy

MARCH 10, 2017

Gene therapy developer Tocagen is preparing an initial public stock offering to finance clinical trials of its experimental treatment for a form of brain cancer. Tocagen has applied to the Nasdaq Exchange for a listing under the stock symbol “TOCA.” Read more » Reprints | Share: UNDERWRITERS AND PARTNERS.

San Diego 79

San Diego Pricing Southern California Develop 79

Xconomy

DECEMBER 10, 2018

The stock price of Mitek (NASDAQ:MITK) rose nearly 9 percent on the news, closing at $9.75. The company’s bread and butter has been licensing software for remote document capture, such as bank checks, but it is also developing a new business in digital identification verification. That’s according to a Nov.

Pricing 43

Pricing Acquisition News Software 43

Xconomy

FEBRUARY 2, 2018

Payne (on the right in above photo), and named Mark Herber, vice president of business development and alliance management, as interim president. The unexpected announcement nevertheless sent the price of Arcturus shares spiraling in after-hours trading, falling by $1.38, nearly 19 percent, to.

Arcturus 56

Arcturus San Diego Pricing Report 56

Xconomy

MARCH 20, 2017

Japan’s Murata Manufacturing has acquired Arctic Sand Technologies of Burlington, MA, and plans to combine Arctic Sand’s low-power semiconductor technology with its San Diego-based subsidiary, Peregrine Semiconductor. The purchase price was $68 million, according to a Peregrine spokeswoman.

San Diego 63

San Diego Mobile Pricing Technology 63

Xconomy

AUGUST 25, 2017

But developments in health policy and life sciences march onward. This week saw some skirmishes in the drug price debate, new plans to expand the. Those of us who stepped outside with eclipse glasses, pin-hole projectors, or even colanders found a brief respite from the news.

Pricing 49

Pricing News Develop Development 49

Xconomy

AUGUST 31, 2020

That price is a 60 percent premium to the Boston-based company’s closing stock price on Friday. Akcea develops drugs for rare diseases. The company currently has two commercialized products, along with others in its pipeline, some of which are in development with large. Read more » Reprints | Share:

Pricing 89

Pricing Product Develop Development 89

Xconomy

SEPTEMBER 17, 2020

Dyne Therapeutics, a company developing genetic medicines for rare muscular disorders, has raised $233 million in an IPO that topped the preclinical-stage biotech’s projections. Late Wednesday, Dyne priced its offering of about 12.3 million shares at $19 each. The Waltham, MA-based biotech had previously planned to sell 10.3

Pricing 114

Pricing Technology Develop Development 114

Xconomy

OCTOBER 6, 2016

San Diego’s Brain Corp. has a vision for developing the kind of technology that could some day be used to operate self-driving cars. Headed by the computational neuroscientist Eugene Izhikevich, the company maintained a low profile at Qualcomm’s San Diego headquarters until 2013, when Brain Corp. Brain Corp.

Product 106

Product Artificial Inteligence San Diego Training 106

Xconomy

MAY 16, 2018

A number of companies are developing drugs to block CGRP and stop migraine pain before it starts. But a common element is the abundance of a pain-inducing protein in the blood. During a migraine attack, nerves release this protein, called calcitonin gene-related peptide (CGRP).

Pricing 77

Pricing Develop Development San Diego 77

Xconomy

OCTOBER 27, 2016

Prices for agricultural commodities such as corn, soy, and wheat are at their lowest levels in years, but investment in agricultural technology has never been better. The increase in dollars flowing to agtech comes despite commodity prices that are down 65 percent from their 2013 peak, the report says. They also queried 15 VC firms.

Venture Capital 40

Venture Capital Pricing Invest Report 40

Xconomy

OCTOBER 28, 2016

. —Two Vertex rivals touted early-stage data at the NACFC conference: Belgium-based Galapagos , which is developing its own triple combination regimen, and Netherlands-based ProQr Therapeutics (NASDAQ: PRQR ), which is advancing an RNA-based CF drug sprayed into the lungs. THIS WEEK IN DRUG PRICING…. billion last year.

Pricing 40

Pricing Conference News Study 40

Xconomy

FEBRUARY 27, 2017

La Jolla Pharmaceutical’s experimental drug to treat a deadly blood pressure condition hit its main goal in a Phase 3 clinical trial, boosting the company’s stock price by more than 75 percent on Monday morning.

San Diego 40

San Diego Study Pricing Organization 40

Xconomy

SEPTEMBER 9, 2016

The scientific goals, writ large, included nationwide data sharing among researchers and drug developers; better prevention through medicine (such as the HPV vaccine) and public education (anti-smoking campaigns); and a registry that could match cancer patients to trials based on genetics and other factors.

Pricing 40

Pricing Startup News Screening 40

Xconomy

DECEMBER 20, 2016

An Acadia Pharmaceuticals drug developed to treat hallucinations and delusions experienced by Parkinson’s disease patients is now showing signs it could also treat similar psychoses associated with Alzheimer’s disease. Investors cheered the news, boosting Acadia’s stock price 13.6 percent to $28.88 in trading Tuesday morning.

San Diego 40

San Diego Statistics Study News 40

Xconomy

AUGUST 10, 2018

Two imminent FDA rulings on two separate drugs aren’t just noteworthy for the patients they’ll help, but the long and winding road their developers have taken to get to this point. First is Alnylam Pharmaceuticals, which has spent 16 years and over $2 billion to try to bring an unproven form of medicine, RNA interference (RNAi), to market.

News 57

News Pricing Help Marketing 57

Xconomy

FEBRUARY 21, 2020

The price of insulin, a life-saving treatment discovered a century ago, has been a flashpoint amid the broader drug pricing debate. The FDA is trying to tame high insulin prices by encouraging price competition. The FDA has historically regarded insulin as a drug.

Pricing 79

Pricing Competition Product Marketing 79

Xconomy

MAY 24, 2019

Patients, doctors, family members, and drug-price watchdogs continued to wait for the expected approval of Zolgensma , a Novartis (NYSE: NVS ) gene therapy for the rare inherited disease spinal muscular atrophy. Originally developed at a children’s hospital in Ohio , Zolgensma will be a litmus test for the nascent field.

Pricing 86

Pricing Marketing Develop Development 86

Xconomy

SEPTEMBER 7, 2016

Retrophin , the drug developer founded by controversial former biotech executive Martin Shkreli, has posted positive results from a midstage study for its treatment for a rare kidney disease. He licensed the drug from San Diego-based Ligand Pharmaceuticals (NASDAQ: LGND ) in March 2012. to $30 apiece. to $30 apiece.

San Diego 40

San Diego Pricing Study Journal 40

Xconomy

JANUARY 12, 2018

But the commercial challenge facing its developer, Spark Therapeutics, is daunting. After decades of research and scientific ups and downs, the first U.S. gene therapy, a single, long-lasting treatment called voretigene neparvovec (Luxturna) for rare, inherited blindness, is now on the market.

Pricing 55

Pricing Research Marketing Develop 55

Xconomy

NOVEMBER 20, 2019

Drug pricing debates and uncertainty associated with Brexit are the issues most likely to keep biopharmaceutical executives awake at night. In turn, pricing pressure is also a concern as corporates and investors plan for the year ahead,”. Nevertheless, senior figures remain optimistic about the industry’s prospects in 2020.

Pricing 78

Pricing Invest Develop Development 78

Xconomy

JUNE 3, 2019

Two weeks after raising $40 million to push ahead with its drug development programs, Inhibrx submitted paperwork to the SEC revealing that it aims to raise money in the public market, too. The La Jolla, CA-based company, which is developing protein drugs targeting cancer and other diseases, was founded in 2010.

Funding 79

Funding Pricing Invest Develop 79

Xconomy

JULY 7, 2016

In 2014, Pernix, then based in The Woodlands, TX, acquired San Diego-based Somaxon Pharmaceuticals. Consequently, Pernix’s stock price has suffered. Last month, Pernix disclosed that it risked delisting from the Nasdaq because its stock price had fallen below $1. Last year, Pernix reported a $148.3 million net loss.

Sales 40

Sales San Diego .Net Report 40

Xconomy

JULY 24, 2020

EQRx launched in January during the JP Morgan Healthcare Conference with an audacious pledge to create 10 new drugs in as many years and then sell them at “dramatically” lower prices than existing medicines. Both drugs are anti-cancer molecules in mid-stage development that have been designed to hit known cancer targets. But not much.

Patents 77

Patents Conference Pricing Design 77

Xconomy

APRIL 23, 2019

After a breakout year in 2017, the blockchain sector suffered a series of blows in 2018, from crashing cryptocurrency prices to increased regulatory scrutiny of crypto ventures and deepening skepticism about whether the technology was actually useful.

Report 98

Report Pricing Organization Technology 98

Xconomy

OCTOBER 7, 2016

PRICE FIGHTS. With some caveats, ICER recommended lower prices. —Sarepta Pharmaceuticals (NASDAQ: SRPT ) struck a second deal in as many weeks to develop combination therapies for Duchenne muscular dystrophy. . —The Nobel in Chemistry went to three scientists, in France, the Netherlands, and the U.S.,

Technical Review 77

Technical Review Study Layoffs San Diego 77

Xconomy

FEBRUARY 6, 2019

The South San Francisco, CA, biotech sold 9.25 million shares Wednesday evening priced at $19 apiece, which was the midpoint of its targeted $18 to $20 per share range. Those shares are expected to begin trading on the Nasdaq Thursday under the stock symbol “ALEC.”

Pricing 100

Pricing Develop Development San Diego 100

Xconomy

FEBRUARY 8, 2019

26 hearing before the Senate Committee on Finance to defend their drug pricing practices. A group of top biopharma executives—the full roster isn’t known yet— will testify at a Feb.

Pricing 85

Pricing Report San Diego Company 85

Xconomy

JANUARY 3, 2018

The first gene therapy approved in the United States will cost $850,000, its developer Spark Therapeutics (NASDAQ: ONCE ) announced today.

Pricing 85

Pricing Ideas Develop Development 85